Infinity Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Seth Tasker
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.7yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
Nov 10
Infinity Pharmaceuticals: Waiting For A Deal
Sep 08Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
May 23We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely
Dec 29Investigating Infinity Pharmaceuticals
Nov 25Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans
Jul 18Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now
Jun 03Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?
Apr 13Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?
Feb 19Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?
Jan 15
Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer
Jan 06Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?
Dec 11Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium
Dec 09Infinity Pharmaceutical Reaching Vital New Staging Posts
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$43m |
| Dec 31 2022 | n/a | n/a | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | n/a | n/a | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$44m |
| Jun 30 2021 | n/a | n/a | -US$43m |
| Mar 31 2021 | n/a | n/a | -US$41m |
| Dec 31 2020 | US$1m | US$386k | -US$40m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$653k | US$368k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | n/a | n/a | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$41m |
| Dec 31 2017 | US$1m | US$320k | -US$42m |
Compensation vs Market: Insufficient data to establish whether Seth's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Seth's compensation has increased whilst the company is unprofitable.
CEO
Seth Tasker (44 yo)
7.7yrs
Tenure
US$1,435,444
Compensation
Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 17.5yrs | US$93.08k | 0.24% $ 0.2 | |
| Lead Independent Director | 12yrs | US$125.82k | 0.017% $ 0.01 | |
| Independent Director | 5.9yrs | US$85.58k | 0.0097% $ 0.009 | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Independent Director | 4yrs | US$83.08k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 4yrs | US$759.67k | no data | |
| Chair of Clinical Advisory Board | no data | US$73.08k | 0.012% $ 0.01 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
6.0yrs
Average Tenure
71yo
Average Age
Experienced Board: INFI.Q's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/11 09:09 |
| End of Day Share Price | 2024/03/11 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Infinity Pharmaceuticals, Inc. is covered by 26 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Raymond | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Kantor | Credit Suisse |